Atorvastatin: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links) |
||
| Line 63: | Line 63: | ||
|format=broadtable | |format=broadtable | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Revision as of 17:25, 20 March 2026
Administration
- Type: Statins (HMG-CoA Reductase Inhibitor)
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Lipitor
Adult Dosing
Hyperlipidemia
- Moderate Intensity: 10-20 mg PO daily
- High Intensity: 40-80 mg PO daily
Acute coronary syndrome
- 80 mg PO (Single dose prior to PCI)
Pediatric Dosing
Special Populations
- Pregnancy Rating: X
- Lactation risk: Generally not recommended while breastfeeding
- Renal Dosing
- No adjustment
- Hepatic Dosing
- Contraindicated in patients with active liver disease
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: Approximately 14 hours[1]
- Metabolism: Metabolized by cytochrome CYP3A4
- Excretion: Metabolites are eliminated via bile.
Mechanism of Action
- Inhibits rate-limiting step in cholesterol biosynthesis by inhibiting HMG-COA reductase.
- Additionally known to have "pleiotropic effects", which include plaque stabilization, improved endothelial function, decreased oxidative stress and inflammation, and thrombogenic response inhibition.[2]
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| ST-segment elevation myocardial infarction | 80 mg PO | High-intensity statin (start in ED) | PO | Adult |
See Also
References
- ↑ McIver LA, Siddique MS. Atorvastatin. [Updated 2022 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/
- ↑ Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748. PMID: 15822172; PMCID: PMC2694580.